MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592386 | Name: Dipivefrin hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dipivefrin hydrochloride is an Antiglaucoma Agent.

Chemical Structure

Dipivefrin hydrochloride
Dipivefrin hydrochloride
CAS#64019-93-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 592386

Name: Dipivefrin hydrochloride

CAS#: 64019-93-8 (HCl)

Chemical Formula: C19H30ClNO5

Exact Mass: 0.0000

Molecular Weight: 387.90

Elemental Analysis: C, 58.83; H, 7.80; Cl, 9.14; N, 3.61; O, 20.62

Price and Availability

Size Price Availability Quantity
25mg USD 300.00 2 Weeks
50mg USD 550.00 2 weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
52365-63-6 (free base) 64019-93-8 (HCl) 56298-24-9 (R-isomer) 79071-01-5 (R-isomer HCl) 149494-91-7 (S-isomer) 133815-41-5 (S-isomer HCl)
Synonym
Dipivefrin hydrochloride; Pivalephrine; Diopine; D Epifrin; Propine; Diphemin; Dipivefrine hydrochloride; Dipivefrine HCl;
IUPAC/Chemical Name
[2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate;hydrochloride
InChi Key
VKFAUCPBMAGVRG-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H29NO5.ClH/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6;/h8-10,13,20-21H,11H2,1-7H3;1H
SMILES Code
[H]Cl.CC(C)(C)C(OC1=CC=C(C(O)CNC)C=C1OC(C(C)(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Dipivefrin hydrochloride (Dipivefrine hydrochloride) is an antiglaucoma prodrug that is hydrolyzed to the active compound, epinephrine, by esterases in the cornea.
In vitro activity:
TBD
In vivo activity:
These experiments examined the effects, in mice, of post-training i.p. injections of dipivefrin (DPE), a lipophilic prodrug of epinephrine, and epinephrine (EPI) on 48-h retention assessed in inhibitory avoidance and Y-maze discrimination tasks. DPE, in doses of 0.3-10 micrograms/kg significantly facilitated retention: the effects were approximately 10-fold more potent than those of EPI obtained with similar experimental conditions. The alpha-adrenergic antagonists prazosin (alpha 1; 3.0 mg/kg; i.p.), yohimbine (alpha 2; 3.0 mg/kg; i.p.) and phentolamine (alpha 1 and alpha 2; 3.0 mg/kg; i.p.) did not block the enhancement of retention induced by either DPE (10.0 micrograms/kg; i.p.) or EPI (0.1 mg/kg; i.p.). However, the beta-adrenergic antagonist propranolol (2.0 mg/kg; i.p.) attenuated the effects of both DPE and EPI. Sotalol (2.0 mg/kg; i.p.), a peripherally-acting beta-adrenergic antagonist, attenuated the effects of EPI but not those of DPE. These findings suggest the DPE-induced enhancement of memory involves central beta- but not alpha-adrenergic mechanisms while EPI's effects are initiated by activation of peripheral beta-adrenergic systems. Reference: Brain Res. 1992 Feb 14;572(1-2):81-6. https://pubmed.ncbi.nlm.nih.gov/1319277/
Solvent mg/mL mM
Solubility
Water 78.0 201.08
DMSO 55.5 143.08
Ethanol 55.5 143.08
PBS (pH 7.2) 10.0 25.78
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 387.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Alkholief M, Kalam MA, Almomen A, Alshememry A, Alshamsan A. Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo. Saudi Pharm J. 2020 Aug;28(8):1019-1029. doi: 10.1016/j.jsps.2020.07.001. Epub 2020 Jul 6. PMID: 32792847; PMCID: PMC7414100. 2. Introini-Collison I, Saghafi D, Novack GD, McGaugh JL. Memory-enhancing effects of post-training dipivefrin and epinephrine: involvement of peripheral and central adrenergic receptors. Brain Res. 1992 Feb 14;572(1-2):81-6. doi: 10.1016/0006-8993(92)90454-h. PMID: 1319277.
In vitro protocol:
TBD
In vivo protocol:
1. Alkholief M, Kalam MA, Almomen A, Alshememry A, Alshamsan A. Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo. Saudi Pharm J. 2020 Aug;28(8):1019-1029. doi: 10.1016/j.jsps.2020.07.001. Epub 2020 Jul 6. PMID: 32792847; PMCID: PMC7414100. 2. Introini-Collison I, Saghafi D, Novack GD, McGaugh JL. Memory-enhancing effects of post-training dipivefrin and epinephrine: involvement of peripheral and central adrenergic receptors. Brain Res. 1992 Feb 14;572(1-2):81-6. doi: 10.1016/0006-8993(92)90454-h. PMID: 1319277.
1: Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev. 2017 Feb 23;2:CD010746. doi: 10.1002/14651858.CD010746.pub2. Review. PubMed PMID: 28231380; PubMed Central PMCID: PMC5477062. 2: Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol. 2016 Nov 18;9(11):1684-1690. eCollection 2016. Review. PubMed PMID: 27990376; PubMed Central PMCID: PMC5145101. 3: Nakamura-Shibasaki M, Latief MA, Ko JA, Funaishi K, Kiuchi Y. Effects of topical adrenergic agents on prostaglandin E2-induced aqueous flare and intraocular pressure elevation in pigmented rabbits. Jpn J Ophthalmol. 2016 Mar;60(2):95-102. doi: 10.1007/s10384-016-0428-2. Epub 2016 Feb 2. PubMed PMID: 26832333. 4: Schramm MJ, Everitt BJ, Milton AL. Bidirectional Modulation of Alcohol-Associated Memory Reconsolidation through Manipulation of Adrenergic Signaling. Neuropsychopharmacology. 2016 Mar;41(4):1103-11. doi: 10.1038/npp.2015.248. Epub 2015 Aug 17. PubMed PMID: 26279079; PubMed Central PMCID: PMC4663661. 5: Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011 Sep;93(3):271-83. doi: 10.1016/j.exer.2011.04.002. Epub 2011 Apr 20. Review. PubMed PMID: 21524649. 6: Choi H, Lee Y, Yeon S, Lee H, Lee H. Effects of anti-glaucoma drugs on resistive index of the medial long posterior ciliary artery using color Doppler imaging in Beagle dogs. J Vet Sci. 2011 Mar;12(1):99-101. PubMed PMID: 21368570; PubMed Central PMCID: PMC3053475. 7: Akaishi T, Odani-Kawabata N, Ishida N, Nakamura M. Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther. 2009 Oct;25(5):401-8. doi: 10.1089/jop.2009.0006. PubMed PMID: 19857101. 8: Bussières JF, Therrien R, Hamel P, Barret P, Prot-Labarthe S. Retrospective cohort study of 163 pediatric glaucoma patients. Can J Ophthalmol. 2009 Jun;44(3):323-7. doi: 10.3129/i09-065. PubMed PMID: 19491991. 9: Aptel F, Denis P. [Retina and glaucoma: therapeutic considerations]. J Fr Ophtalmol. 2008 Jul;31(6 Pt 2):2S61-4. Review. French. PubMed PMID: 18957916. 10: Hori N, Takamori M, Hirayama M, Watanabe H, Nakamura T, Yamashita F, Ito H, Mabuchi N, Sobue G. Pupillary supersensitivity and visual disturbance in Parkinson's disease. Clin Auton Res. 2008 Feb;18(1):20-7. doi: 10.1007/s10286-008-0453-4. Epub 2008 Feb 11. PubMed PMID: 18265941. 11: Neu F. [Cystoid macular edema]. Bull Soc Belge Ophtalmol. 2007;(304):71-6. Review. French. PubMed PMID: 17718230. 12: Wu KY, Wang HZ, Hong SJ. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci. 2007 Mar;23(3):105-11. PubMed PMID: 17389174. 13: Kalavala M, Statham BN. Allergic contact dermatitis from timolol and dorzolamide eye drops. Contact Dermatitis. 2006 Jun;54(6):345. PubMed PMID: 16787459. 14: Wu KY, Wang HZ, Hong SJ. Effects of antiglaucoma drugs on cellular proliferation in cultured human corneal keratocytes. Kaohsiung J Med Sci. 2006 Mar;22(3):120-5. PubMed PMID: 16602276. 15: Wu KY, Hong SJ, Wang HZ. Effects of antiglaucoma drugs on calcium mobility in cultured corneal endothelial cells. Kaohsiung J Med Sci. 2006 Feb;22(2):60-7. PubMed PMID: 16568722. 16: Vilaplana J, Zaballos P, Romaguera C. Contact dermatitis by dipivefrine. Contact Dermatitis. 2005 Mar;52(3):169-70. PubMed PMID: 15811042. 17: Călugăru M, Călugăru D. [Latanoprost topical ophthalmic combinations]. Oftalmologia. 2004;48(4):18-28. Review. Romanian. PubMed PMID: 15782758. 18: Wu KY, Wang HZ, Hong SJ. Inhibition of endothelin-1 and KCL-induced increase of [CA2+]i by antiglaucoma drugs in cultured A7r5 vascular smooth-muscle cells. J Ocul Pharmacol Ther. 2004 Jun;20(3):201-9. PubMed PMID: 15279725. 19: Fröhlich SJ, Mueller AJ, Kampik A. [Relative contraindication of latanoprost in iris tumors with secondary glaucoma]. Ophthalmologe. 2003 Aug;100(8):633-8. German. PubMed PMID: 12955445. 20: Hong SJ, Wu KY, Wang HZ, Fong JC. Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells. J Ocul Pharmacol Ther. 2003 Jun;19(3):205-15. PubMed PMID: 12828839.